AVANIA
Avania , a leading global medical technology CRO, today announced its acquisition of IMARC, a highly respected medical device CRO headquartered in Strongsville, Ohio and providing service throughout the United States. IMARC brings more than two decades of full-service clinical research oversight to its clients, including monitoring, auditing, safety, data management, and training.
“At Avania, we are focused on building a high-quality, full-service specialist medical technology CRO with global reach,” said Avania CEO Sapna Hornyak. “We are delighted to welcome the IMARC team, with whom we have had the pleasure of collaborating for some time. They bring a great commitment to client service and outcomes and allow us to offer our clients additional depth and strength in the United States, complementing our existing global operations perfectly.”
IMARC clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the EU and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, strategic consulting, regulatory, and medical writing.
“Avania’s geographic and therapeutic area strengths make them the perfect strategic complement to IMARC,” said IMARC CEO Sandra Maddock. “Adding IMARC’s portfolio of capabilities to Avania’s will provide clients with a single-source provider of extensive, specialized medical device expertise combined with global reach.”
Covington Associates, a leading middle market investment bank, acted as exclusive financial advisor to IMARC in its sale to Avania.
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
About IMARC
IMARC assists clinical researchers pursuing FDA and worldwide approvals by preparing, educating, and guiding site teams from Day One to control the complex management of trials via cost-effective monitoring, auditing, and training services — resulting in the support, proof, and assurance they seek to overcome chaos caused by complexity while achieving compliance through consistency — based on competent, committed consultation and setting the highest standards for site outcomes and study partnerships.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press release
At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra
PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press release
PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s
FIFA World Cup™ Trophy Tour by Coca-Cola to Begin Global Journey Ahead of FIFA World Cup 2026™16.12.2025 14:00:00 CET | Press release
Coca-Cola and FIFA celebrate 20 years of FIFA World Cup™ Trophy Tour by Coca-Cola The Coca-Cola Company and FIFA are kicking off the sixth FIFA World Cup™ Trophy Tour by Coca-Cola, giving thousands of fans across the globe the opportunity to see the original FIFA World Cup™ Trophy ahead of FIFA World Cup 2026™. FIFA World Cup 2026 is set to be the biggest yet—spanning three host nations, Canada, Mexico and the United States, with more teams, more matches and more celebrations than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216393608/en/ FIFA World Cup™ Trophy Tour by Coca-Cola As a long-standing partner of FIFA, Coca-Cola has the exclusive rights to the FIFA World Cup Trophy Tour by Coca-Cola. Beginning Jan. 3, 2026, in Riyadh, Saudi Arabia, the original FIFA World Cup Trophy will visit 30 FIFA Member Associations across 75 stops and more than 150 tour days, giving fans around the world a once-in-a-lifeti
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom